New hope for pancreatic cancer: combo therapy aims to improve surgery success

NCT ID NCT07542002

Recruiting now Disease control Sponsor: Ningbo Medical Center Lihuili Hospital Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tests a combination of chemotherapy drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin), an immunotherapy (adebrelimab), and radiation therapy before surgery for people with pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach can increase the chance of a complete surgical removal (R0 resection) and improve survival. About 37 participants will receive four cycles of the drug combination plus five sessions of short-course radiation before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ningbo Medical Center Lihuili Hospital
RECRUITING

Ningbo, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PANCREATIC CANCER